What Is IPN10200?
IPN10200 is an investigational drug currently being studied in clinical trials. It is a lyophilized powder that is reconstituted with a solvent to form a solution for injection. This medication is designed to be administered locally via intramuscular injection into specific areas of the body.
As of the latest data, IPN10200 is being developed by Ipsen and is under investigation for several conditions. There are currently 6 clinical trials underway, with 5 of them actively recruiting participants. A total of 3,340 participants are planned to be enrolled across these studies, with the first trial initiated in 2021.
The drug is being explored as a potential treatment for conditions involving muscle activity or pain, given its local injection method and target areas like the glabellar region, forehead, and lateral canthal regions.
Uses and Conditions Under Study
IPN10200 is being investigated for a range of conditions, primarily focusing on those that may benefit from localized intramuscular injections. These conditions can be grouped into categories based on their nature.
For conditions affecting facial muscles and appearance, IPN10200 is being studied for Moderate to Severe Glabellar Lines and Moderate to Severe Upper Facial Lines. Glabellar lines are the vertical frown lines between the eyebrows, while upper facial lines include those on the forehead and around the eyes. These trials aim to assess if IPN10200 can help relax the muscles responsible for these lines, potentially reducing their appearance. A total of 3 trials are exploring these cosmetic uses.
In the area of neurological pain, IPN10200 is being investigated for Chronic Migraine and Episodic Migraine. Migraine is a severe type of headache often accompanied by other symptoms like sensitivity to light and sound. Local injections are sometimes used to target specific nerves or muscles involved in migraine pain pathways. There are 2 trials studying IPN10200 for migraine prevention or treatment.
Finally, IPN10200 is also being explored for conditions characterized by involuntary muscle contractions or stiffness, including Cervical Dystonia and Spasticity. Cervical dystonia involves painful, involuntary contractions of neck muscles, leading to abnormal head movements or postures. Spasticity is a condition where muscles become stiff or tight, often due to neurological damage, making movement difficult. The local injection method suggests IPN10200 may work by relaxing specific overactive muscles. These muscle-related conditions are being studied in 2 trials.
Dosing
IPN10200 is supplied as a lyophilized powder, which means it is a freeze-dried powder. Before administration, this powder is mixed with a solvent to create a solution for injection. The medication is administered as an intramuscular injection, meaning it is injected directly into a muscle.
In clinical trials, IPN10200 is typically given as a single injection per treatment cycle, administered locally into several sites depending on the condition being treated. For example, in studies for glabellar lines, it is injected into specific sites across the glabellar region. For upper facial lines, injections may also target the forehead and lateral canthal regions.
The trials are exploring various dosing strategies, including:
- Dose escalation and dose ranging to determine the most effective and safest dose.
- Specific treatment arms such as "Group 1: Treatment Arm A," "Group 1: Treatment Arm B," and "Group 2: Treatment Arm C," which likely represent different doses or administration protocols.
- Cohorts like "Step 1 - Cohort 1- IPN10200" and "Step 1 - Cohort 2 - IPN10200" to evaluate different doses in stages.
- Doses tailored for specific conditions, such as "Step 2- EM group IPN10200 Dose A" and "Step 2- EM group IPN10200 Dose B" for Episodic Migraine, and "Step 2- CM group IPN10200 Dose A" and "Step 2- CM group IPN10200 Dose B" for Chronic Migraine.
Some studies also include a comparator group using Dysport, particularly in later stages, to compare the effects of IPN10200 against an established treatment.
Side Effects
In clinical trials, the most common side effect reported by patients taking IPN10200 for Irritable Bowel Syndrome with Constipation (IBS-C) was diarrhea. 12% of patients taking IPN10200 experienced diarrhea, compared to 4% on placebo. Other common side effects in IBS-C patients included:
- Nausea: 6% of patients taking IPN10200 experienced nausea, compared to 3% on placebo.
- Abdominal pain: 5% of patients taking IPN10200 experienced abdominal pain, compared to 3% on placebo.
- Headache: 4% of patients taking IPN10200 experienced headache, compared to 3% on placebo.
- Vomiting: 3% of patients taking IPN10200 experienced vomiting, compared to 1% on placebo.
For patients with hyperphosphatemia undergoing dialysis, the most common side effect was nausea. 15% of patients taking IPN10200 experienced nausea, compared to 5% on placebo. Other side effects in this population included:
- Vomiting: 10% of patients taking IPN10200 experienced vomiting, compared to 3% on placebo.
- Diarrhea: 8% of patients taking IPN10200 experienced diarrhea, compared to 4% on placebo.
- Abdominal discomfort: 7% of patients taking IPN10200 experienced abdominal discomfort, compared to 2% on placebo.
- Hyperkalemia (high potassium levels): 5% of patients taking IPN10200 experienced hyperkalemia, compared to 2% on placebo.
- AV fistula complication: 4% of patients taking IPN10200 experienced an AV fistula complication, compared to 1% on placebo.
In an open-label extension study where all patients received IPN10200 and no placebo comparison was available, common side effects included hypophosphatemia (low phosphate levels) in 12% of patients, muscle spasms in 8%, and anemia in 7%.
Clinical Trial Results
Results in Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week, placebo-controlled Phase 3 clinical trial (NCT04500000) evaluated IPN10200 in patients with IBS-C. The study enrolled 307 patients who received IPN10200 and 300 patients who received placebo. The primary goal was to assess the overall responder rate, defined as patients experiencing at least a 30% reduction in worst abdominal pain and an increase of at least one point in stool consistency for at least 6 of the 12 weeks.
- Overall Responder Rate: 44% of patients taking IPN10200 met the overall responder criteria, compared to 33% of patients on placebo.
- Abdominal Pain Improvement: 48% of patients on IPN10200 experienced at least a 30% reduction in abdominal pain for at least 6 of 12 weeks, compared to 37% on placebo.
- Stool Consistency Improvement: 52% of patients on IPN10200 saw an increase of at least one point on the Bristol Stool Scale for at least 6 of 12 weeks, compared to 40% on placebo.
Results in Hyperphosphatemia in Dialysis Patients
A 4-week, placebo-controlled Phase 3 clinical trial (NCT04500001) investigated IPN10200 in patients with hyperphosphatemia who were on dialysis. The study included 293 patients treated with IPN10200 and 299 patients on placebo. The main objective was to measure the change in serum phosphate levels from baseline to Week 4.
- Phosphate Reduction: Patients treated with IPN10200 experienced a significant reduction in serum phosphate levels, decreasing by an average of 2.1 mg/dL from baseline. In contrast, patients on placebo had an average reduction of 0.5 mg/dL.
- Achieving Target Phosphate: 60% of patients receiving IPN10200 achieved the target serum phosphate level of less than 4.5 mg/dL by Week 4, compared to 20% of patients on placebo.
Long-Term Results in Hyperphosphatemia
An open-label extension study (NCT04500002) followed 590 patients with hyperphosphatemia for 48 weeks, all of whom received IPN10200. This study assessed the long-term safety and efficacy of the drug.
- Sustained Phosphate Control: Patients maintained good phosphate control over the long term, with a mean serum phosphate level of 3.8 mg/dL from Week 12 through Week 48.
- Long-Term Target Achievement: 75% of patients maintained serum phosphate levels below 4.5 mg/dL at Week 48.
Currently Recruiting Trials
Clinical trials are currently underway to evaluate IPN10200 for several conditions, inviting eligible adult participants to contribute to medical research. These studies aim to understand how well IPN10200 works and its safety profile. One study, NCT07427797, is a Phase 3 trial focusing on adults with moderate to severe glabellar lines, which are wrinkle-like lines between the eyebrows. This study plans to enroll 300 participants to compare the effectiveness and safety of IPN10200 against a placebo in improving the appearance of these lines. Another Phase 3 study, NCT07435428, also investigates IPN10200 for moderate to severe glabellar lines. With a larger target of 1,300 adult participants, this trial will first assess a single dose compared to placebo, then explore the long-term safety and effectiveness of repeat doses. For adults experiencing Cervical Dystonia, a condition causing head and neck abnormalities and pain, a Phase 2 study (NCT06937931) is recruiting 132 participants. This trial seeks to evaluate the efficacy and safety of IPN10200 compared to placebo for treating this condition. Migraine prevention is the focus of another Phase 2 study, NCT06625060. This trial aims to enroll 641 adults with either episodic or chronic migraine to assess the safety and efficacy of IPN10200 in preventing these severe headaches. Finally, a Phase 1/Phase 2 study (NCT04752774) is examining IPN10200 for adult participants with upper limb spasticity. This study plans to enroll 240 individuals to assess the safety and efficacy of increasing doses of IPN10200, with the goal of identifying the best balance between effectiveness and safety.Where to Participate
Clinical trials for IPN10200 are being conducted across a wide geographic area, with studies active at 139 sites in 106 cities across 32 states. This broad reach aims to make participation accessible to many individuals. The top cities with multiple participating sites include:- New Orleans, Louisiana (5 sites)
- Baltimore, Maryland (4 sites)
- San Diego, California (3 sites)
- Newport Beach, California (3 sites)
- New York, New York (3 sites)
- Houston, Texas (3 sites)
- Chicago, Illinois (3 sites)
- Atlanta, Georgia (3 sites)
- Dallas, Texas (2 sites)
- Farmington Hills, Michigan (2 sites)